A research team has developed a unique linker technology to connect a synthetic drug delivery vehicle referred to as a nucleic acid nanocapsule (NAN) with a new peptide cross-linker approach. The NAN enables both a small molecule drug and a nucleic acid -- RNA or DNA -- to be delivered to a cell. This combination generates a nanocapsule capable of shepherding genetic or pharmaceutical molecules to a target on or within a cell.